Larry Peiperl, MD
MD Link/Epiccare Link Access
Cio
Chancellor/EVC/FAS

Education & Training

Show all (2) Hide

• M.D. School of Medicine University of California, San Francisco 1992
• Residency School of Medicine University of California, San Francisco

Publications (3)

Top publication keywords:
Double-Blind MethodDefective VirusesEnzyme-Linked Immunospot AssayAcquired Immunodeficiency SyndromeEnzyme-Linked Immunosorbent AssayHIV-1AIDS VaccinesAntibodies, NeutralizingT-LymphocytesAntiretroviral Therapy, Highly ActiveCD4 Lymphocyte CountHIV AntibodiesAdenoviridaeVaccinationPlacebos

• Phase I/II randomized trial of safety and immunogenicity of LIPO-5 alone, ALVAC-HIV (vCP1452) alone, and ALVAC-HIV (vCP1452) prime/LIPO-5 boost in healthy, HIV-1-uninfected adult participants.
  Clinical and vaccine immunology : CVI 2014 Frey SE, Peiperl L, McElrath MJ, Kalams S, Goepfert PA, Keefer MC, Baden LR, Lally MA, Mayer K, Blattner WA, Harro CD, Hammer SM, Gorse GJ, Hural J, Tomaras GD, Levy Y, Gilbert P, deCamp A, Russell ND…
• Safety and immunogenicity of a replication-defective adenovirus type 5 HIV vaccine in Ad5-seronegative persons: a randomized clinical trial (HVTN 054).
  PloS one 2010 Peiperl L, Morgan C, Moodie Z, Li H, Russell N, Graham BS, Tomaras GD, De Rosa SC, McElrath MJ, NIAID HIV Vaccine Trials Network
• Low CD4+ T cell nadir is an independent predictor of lower HIV-specific immune responses in chronically HIV-1-infected subjects receiving highly active antiretroviral therapy.
  The Journal of infectious diseases 2006 Siddique MA, Hartman KE, Dragileva E, Dondero M, Gebretsadik T, Shintani A, Peiperl L, Valentine F, Kalams SA